eGene's DNA Analyzer Used for Anti-Tumor Medication-Related Large-Scale Population Genotyping; Report Indicates Analyzer is a Highly Efficient Technique in a Clinical Laboratory Setting for Genotyping Related to Anti-Tumor Medication
IRVINE, Calif., Apr 25, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that its analyzer was used in large-scale screening for genotyping related to anti-tumor medication and was found to be a highly efficient tool in a clinical laboratory setting. The research report will be published in the coming issue of Analytical Biochemistry 352 (2006) 148-150.
Dr. Ming S. Liu, acting CEO of eGene, noted: "A recent study has demonstrated that the determination of a certain individual genotype will be essential to future anti-tumor medication. The genotype of an enzyme (deoxycytidine Kinase) in our body may represent a significant influence on the efficacy for acute myeloid leukemia treatment. The result of genotyping will not only provide information for patient treatment, but also indicate the direction of future cancer drug development.
"The best way for future medication would be to identify the individual genotype of certain genes and treat the disease with the right medicine," he continued. "Our HDA-GT12 genetic analyzer could play a major role in genotyping analysis. It is a compact, low-cost, automated digital genotyping system, which will be useful in hospitals, outpatient facilities, clinical laboratories and the pharmaceutical industry for medication-related genotyping analysis."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr.com
Copyright Business Wire 2006
